March 27, 2018 / 11:46 AM / 23 days ago

BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update

March 27 (Reuters) - Antares Pharma Inc:

* ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE

* BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION

* ANTARES PHARMA -ANTICIPATES RESUBMISSION TO INCLUDE RE-ANALYSES OF EXISTING DATA, ADDRESS LABELING, POTENTIAL POST-APPROVAL RISK MITIGATION STRATEGIES

* ANTICIPATES SUBMITTING COMPLETE RESPONSE IN Q2 OF THIS YEAR

* OFFICIAL MINUTES FROM TYPE A MEETING WITH FDA ON FEB. 21 HAVE BEEN RECEIVED Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below